ARHGEF38-IT1: A Potential Drug Target and Biomarker (G100874374)

Target Name: ARHGEF38-IT1

NCBI ID: G100874374

ARHGEF38-IT1

Other Name(s): ARHGEF38 intronic transcript 1

ARHGEF38-IT1: A Potential Drug Target and Biomarker

ARHGEF38-IT1 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a crucial role in cellular signaling. Activation of GPCR receptors can lead to various physiological effects, including modulation of gene expression, protein synthesis, and cellular signaling pathways.

Recent studies have identified ARHGEF38-IT1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. In this article, we will provide an overview of ARHGEF38-IT1, its potential drug target properties, and its potential as a biomarker for disease.

Potential Drug Target and Biomarker Properties of ARHGEF38-IT1

ARHGEF38-IT1 has been identified as a potential drug target due to its involvement in various cellular signaling pathways. Activation of ARHGEF38-IT1 has been shown to modulate the activity of several intracellular signaling pathways, including the tyrosine signaling pathway, the serotonin signaling pathway, and the NF-kappa-B signaling pathway.

ARHGEF38-IT1 is a GPCR receptor that is involved in the regulation of various physiological processes in the body, including blood pressure, bone density, and inflammation. Activation of ARHGEF38-IT1 has been shown to increase the activity of several intracellular signaling pathways, including the tyrosine signaling pathway. This increase in activity can lead to the activation of transcription factors, such as STAT3, which can then lead to the expression of various genes that are involved in the regulation of inflammation, cell survival, and metabolism.

ARHGEF38-IT1 has also been shown to play a role in the regulation of pain perception. Activation of ARHGEF38-IT1 has been shown to modulate the activity of several pain modulatory proteins, including TrkA, TrkB, and endogenous opioids. This modulation of pain modulatory proteins can lead to the alleviation of pain.

In addition to its potential drug target properties, ARHGEF38-IT1 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The expression of ARHGEF38-IT1 has been shown to be elevated in various tissues of cancer, neurodegenerative diseases, and cardiovascular diseases. This increase in expression can be used as a diagnostic or predictive marker for these diseases.

Conclusion

In conclusion, ARHGEF38-IT1 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its involvement in various cellular signaling pathways makes it an attractive target for small molecules. Further studies are needed to fully understand the potential of ARHGEF38-IT1 as a drug target and biomarker.

Protein Name: ARHGEF38 Intronic Transcript 1

The "ARHGEF38-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF38-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets